TAILIEUCHUNG - Plagemann et al. Health Economics Review 2011, 1:1

Plagemann et al. Health Economics Review 2011, 1:1 REVIEW Open Access Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia Thomas Plagemann1, Anne Prenzler2* and Thomas Mittendorf1 Abstract Because of an elevated serum phosphate level, patients who suffer from chronic kidney failure frequently tend to have cardiovascular calcification and are therefore exposed to a higher probability of a fatal event. Phosphate binders are able to reduce these negative effects. Currently, there are primarily two groups of phosphate binders (calcium-containing and calcium-free phosphate binders) which are considered to be almost equally effective in terms of binding of free phosphate. There. | Plagemann et al. Health Economics Review 2011 1 1 http content 1 1 1 o Health Economics Review a SpringerOpen Journal REVIEW Open Access Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia Thomas Plagemann1 Anne Prenzler2 and Thomas Mittendorf1 Abstract Because of an elevated serum phosphate level patients who suffer from chronic kidney failure frequently tend to have cardiovascular calcification and are therefore exposed to a higher probability of a fatal event. Phosphate binders are able to reduce these negative effects. Currently there are primarily two groups of phosphate binders calcium-containing and calcium-free phosphate binders which are considered to be almost equally effective in terms of binding of free phosphate. There are however a few disadvantages of the two groups. While the calcium-containing binders are associated with an increased risk of hypercalcaemia which is dose dependent calcium-free binders have been criticized as being too expensive. As the expenditure for patients suffering from chronic kidney failure increases from year to year as a result of increasing prevalence there is a growing need for an alternative to existing phosphate binders. The study presented here therefore summarizes available information for the novel combination preparation OsvaRen calcium acetate magnesium carbonate as an alternative therapy to the calcium-free phosphate binder Renagel sevelamer-hydrochloride and to calcium-containing preparations. The results of this systematic review showed that OsvaRen is at least equally effective in the regulation of serum phosphate level as Renagel . In particular OsvaRen shows no clinically relevant difference in terms of the control of the serum calcium levels compared to Renagel and thereby does not increase the risk of a hypercalcaemia in contrast to pure calcium-based phosphate binders. On the other hand Renagel therapy is much more

TÀI LIỆU LIÊN QUAN
TAILIEUCHUNG - Chia sẻ tài liệu không giới hạn
Địa chỉ : 444 Hoang Hoa Tham, Hanoi, Viet Nam
Website : tailieuchung.com
Email : tailieuchung20@gmail.com
Tailieuchung.com là thư viện tài liệu trực tuyến, nơi chia sẽ trao đổi hàng triệu tài liệu như luận văn đồ án, sách, giáo trình, đề thi.
Chúng tôi không chịu trách nhiệm liên quan đến các vấn đề bản quyền nội dung tài liệu được thành viên tự nguyện đăng tải lên, nếu phát hiện thấy tài liệu xấu hoặc tài liệu có bản quyền xin hãy email cho chúng tôi.
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.